中华神经科杂志
中華神經科雜誌
중화신경과잡지
Chinese Journal of Neurology
2009年
7期
486-489
,共4页
王蔚%印卫兵%柏建岭%吴婷%丁新生
王蔚%印衛兵%柏建嶺%吳婷%丁新生
왕위%인위병%백건령%오정%정신생
依达拉奉%脑梗死%药物副反应报告系统%随机对照试验%Meta分析
依達拉奉%腦梗死%藥物副反應報告繫統%隨機對照試驗%Meta分析
의체랍봉%뇌경사%약물부반응보고계통%수궤대조시험%Meta분석
Edaravone%Brain infarction%Adverse drug reaction reporting systems%Randomizad controlled trial%Meta-analysis
目的 回顾分析依达拉奉治疗急性脑梗死等国内文献资料中依达拉奉的不良反应.了解依达拉奉不良反应的发生率及其临床应用的安全性.方法 计算机检索Pubmed、中国生物医学文献数据库及所获文献的参考文献,对8645例患者进行不良反应分析,并对依达拉奉治疗急性脑梗死随机对照试验研究应用Meta分析来全面分析依达拉奉的安全性.结果 依达拉奉不良反应最多见的是轻度氨基转移酶升高、肾功能异常及皮疹,不良反应(283例)占总例数(8645例)比例为3.27 % ;共纳入10项依达拉奉治疗急性脑梗死的随机对照试验研究,Meta分析显示:依达拉奉+常规治疗组与常规治疗组的不良事件发生率差异(OR=1.18,95 % CI 0.70-2.00,P=0.536)、氨基转移酶升高发生率差异(OR=1.23,95 % CI 0.57-2.68,P=0.595)以及肾功能异常(蛋白尿、肌酐升高、尿素氮升高)发生率差异(OR=1.65,95 % CI 0.57-4.79,P=0.353)均无统计学意义.结论 依达拉奉的不良反应发生率很低,临床应用较为安全.
目的 迴顧分析依達拉奉治療急性腦梗死等國內文獻資料中依達拉奉的不良反應.瞭解依達拉奉不良反應的髮生率及其臨床應用的安全性.方法 計算機檢索Pubmed、中國生物醫學文獻數據庫及所穫文獻的參攷文獻,對8645例患者進行不良反應分析,併對依達拉奉治療急性腦梗死隨機對照試驗研究應用Meta分析來全麵分析依達拉奉的安全性.結果 依達拉奉不良反應最多見的是輕度氨基轉移酶升高、腎功能異常及皮疹,不良反應(283例)佔總例數(8645例)比例為3.27 % ;共納入10項依達拉奉治療急性腦梗死的隨機對照試驗研究,Meta分析顯示:依達拉奉+常規治療組與常規治療組的不良事件髮生率差異(OR=1.18,95 % CI 0.70-2.00,P=0.536)、氨基轉移酶升高髮生率差異(OR=1.23,95 % CI 0.57-2.68,P=0.595)以及腎功能異常(蛋白尿、肌酐升高、尿素氮升高)髮生率差異(OR=1.65,95 % CI 0.57-4.79,P=0.353)均無統計學意義.結論 依達拉奉的不良反應髮生率很低,臨床應用較為安全.
목적 회고분석의체랍봉치료급성뇌경사등국내문헌자료중의체랍봉적불량반응.료해의체랍봉불량반응적발생솔급기림상응용적안전성.방법 계산궤검색Pubmed、중국생물의학문헌수거고급소획문헌적삼고문헌,대8645례환자진행불량반응분석,병대의체랍봉치료급성뇌경사수궤대조시험연구응용Meta분석래전면분석의체랍봉적안전성.결과 의체랍봉불량반응최다견적시경도안기전이매승고、신공능이상급피진,불량반응(283례)점총례수(8645례)비례위3.27 % ;공납입10항의체랍봉치료급성뇌경사적수궤대조시험연구,Meta분석현시:의체랍봉+상규치료조여상규치료조적불량사건발생솔차이(OR=1.18,95 % CI 0.70-2.00,P=0.536)、안기전이매승고발생솔차이(OR=1.23,95 % CI 0.57-2.68,P=0.595)이급신공능이상(단백뇨、기항승고、뇨소담승고)발생솔차이(OR=1.65,95 % CI 0.57-4.79,P=0.353)균무통계학의의.결론 의체랍봉적불량반응발생솔흔저,림상응용교위안전.
Objective To analyze the adverse drug reactions(ADRs)of edaravone in treatment of patients with acute cerebral infarction(ACI)by reviewing Chinese medical literature and to evaluate safety of edaravone treatment in ACI.Methods Publications from Pubmed and Chinese Biomedical Literature Datababe(CBMdisc)were reviewed and the ADR of edaravone was analyzed among the published 8645 cases.Literatures about randomed-control clinical trails(RCTs)on security of edaravone for treating ACI Was analyzed by meta-analysis.Results Abnormal hepatic function,especially mild elevation of aminotransferase,renal dysfunction and skin rash induced by edaravone were tIle most common ADRs.Among 8645 patients,ADRs were reported in 283(3.27 % ).The meta-analysis in RCTs showed that between the group treated with a combination of edaravone and routine and the group treated with routine treatment only,there was no significant difference in the occurrence rate of ADRs(OR=1.18,95 % CI0.70-2.00,P=0.536),elevation of aminotransferase(OR=1.23,95 % CI 0.57-2.68,P=0.595)or renal dysfunction including albuminutia,increased level of serum ereatinine and nitrogen(OR=1.65.95 % CI0.57- 4.79.P=0.353).Conclusion Edaravone has a low ADRs OCCurrence rate and iS safely used in cerebral infarction treatment.
